Table 1:
Baseline Characteristics For Patients with Device-Detected AF > 1 hour
| Total (N=1,712) |
ICD (N=1,398) |
PPM/ICM (N=314) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Demographics | No OAC (N=1,171) |
OAC (N=227) |
P-value* | No OAC (N=268) |
OAC (N=46) |
P-value* | |||
| Age (mean±SD) | 71.5 ± 9.6 | 71.1 ± 9.5 | 68.9 ± 8.4 | 0.001 | 75.1 ± 9.8 | 73.0 ± 8.0 | 0.18 | ||
| Male | 1,686 (98.5%) | 1,159 (99.0%) | 223 (98.2%) | 0.34 | 259 (96.6%) | 45 (97.8%) | 0.67 | ||
| Race | 0.21 | 0.57 | |||||||
| White | 1,467 (85.7%) | 985 (84.1%) | 199 (87.7%) | 243 (90.7%) | 40 (87.0%) | ||||
| Black | 155 (9.1%) | 117 (10.0%) | 21 (9.3%) | 13 (4.9%) | 4 (8.7%) | ||||
| Clinical AF† | 598 (34.9%) | 388 (33.1%) | 85 (37.4%) | 0.21 | 99 (36.9%) | 26 (56.5%) | 0.01 | ||
| Hypertension | 1,411 (82.4%) | 948 (81.0%) | 199 (87.7%) | 0.02 | 225 (84.0%) | 39 (84.8%) | 0.89 | ||
| Heart Failure | 1,239 (72.4%) | 952 (81.3%) | 203 (89.4%) | 0.0031 | 71 (26.5%) | 13 (28.3%) | 0.80 | ||
| Prior Stroke/TIA | 161 (9.4%) | 108 (9.2%) | 17 (7.5%) | 0.40 | 32 (11.9%) | 4 (8.7%) | 0.52 | ||
| Prior MI | 196 (11.5%) | 141 (12.0%) | 38 (16.7%) | 0.05 | 13 (4.9%) | 4 (8.7%) | 0.29 | ||
| Diabetes | 814 (47.6%) | 556 (47.5%) | 129 (56.8%) | 0.001 | 104 (38.8%) | 25 (54.4%) | 0.05 | ||
| Coronary Artery Disease | 1,267 (74.0%) | 933 (69.8%) | 185 (76.8%) | 0.03 | 147 (43.4%) | 25 (50.0%) | 0.38 | ||
| Peripheral Vascular Disease | 182 (10.6%) | 126 (9.4%) | 22 (9.1%) | 0.88 | 27 (8.0%) | 7 (14.0%) | 0.16 | ||
| Charlson Comorbidity Index (mean±SD) | 3.0 ± 1.7 | 3.1 ± 1.7 | 3.4 ± 1.6 | 0.04 | 2.4 ± 1.7 | 2.4 ± 1.9 | 0.99 | ||
| CHADS2 Score (mean±SD) | 2.5 ± 1.2 | 2.5 ± 1.1 | 2.6 ± 1.0 | 0.10 | 2.2 ± 1.2 | 2.3 ± 1.2 | 0.12 | ||
| CHADS2 Score Group | 0.02 | 0.91 | |||||||
| CHADS2 0–1 | 358 (20.9%) | 226 (19.3%) | 42 (17.4%) | 90 (33.6%) | 14 (30.4%) | ||||
| CHADS2 2–3 | 1,091 (63.7%) | 758 (64.7%) | 167 (73.6%) | 141 (52.6%) | 25 (54.4%) | ||||
| CHADS2 4–6 | 263 (15.4%) | 187 (16.0%) | 32 (14.1%) | 37 (13.8%) | 7 (15.2%) | ||||
| CHA2DS2-VASc Score (mean±SD) | 4.0 ± 1.4 | 4.0 ± 1.4 | 4.1 ± 1.3 | 0.42 | 3.7 ± 1.5 | 3.7 ± 1.5 | 0.91 | ||
| HAS-BLED Score (mean±SD)‡ | 2.6 ± 1.1 | 2.6 ± 1.0 | 2.6 ± 1.1 | 0.52 | 2.7 ± 1.0 | 2.8 ± 1.2 | 0.64 | ||
| Baseline Medications§ | |||||||||
| Aspirin | 385 (22.5%) | 257 (22.0%) | 54 (23.8%) | 0.54 | 64 (23.9%) | 10 (21.7%) | 0.75 | ||
| Clopidogrel | 218 (12.7%) | 149 (12.7%) | 28 (12.3%) | 0.87 | 36 (13.4%) | 5 (10.9%) | 0.63 | ||
| ACE-I/ARB | 929 (54.3%) | 632 (54.0%) | 126 (55.5%) | 0.67 | 146 (54.5%) | 25 (54.4%) | 0.99 | ||
| Diuretic | 821 (48.0%) | 561(47.9%) | 112 (49.3%) | 0.69 | 128 (47.8%) | 20 (43.5%) | 0.59 | ||
| Niacin/Fibrates | 157 (9.2%) | 107 (9.1%) | 13 (5.7%) | 0.09 | 34 (12.7%) | 3 (6.5%) | 0.23 | ||
| Statin | 1,000 (58.4%) | 919 (58.2%) | 218 (56.0%) | 0.43 | 152 (56.7%) | 24 (52.2%) | 0.57 | ||
| Class 1 AAD | 22 (1.3%) | 16(1.4%) | 0 | 0.08 | 5 (1.87%) | 1 (2.2%) | 0.89 | ||
| Class 3 AAD|| | 80 (4.7%) | 54 (4.6%) | 8 (3.5%) | 0.47 | 16 (6.0%) | 2 (4.4%) | 0.66 | ||
| Amiodarone | 97 (5.7%) | 66 (5.6%) | 9 (4.0%) | 0.31 | 17 (6.3%) | 5 (10.9%) | 0.27 | ||
| Beta Blockers | 1,041 (60.8%) | 710 (60.6%) | 141 (62.1%) | 0.68 | 165 (61.6%) | 25 (54.4%) | 0.35 | ||
| Calcium Channel Blockers# | 42 (2.5%) | 26 (2.2%) | 7 (3.1%) | 0.43 | 8 (3.0%) | 1 (2.0%) | 0.76 | ||
Differences between OAC-treated and untreated groups assessed using the chi-squared test and 2-sample t-test for categorical and continuous variables, respectively;
At least one encounter with an International Classification of Diseases, Ninth Revision (ICD-9) code for AF (427.31 or 427.32), in the primary or secondary position, in the 2 years prior to index device-detected AF;
Excludes labile international normalized ratio component;
90 days prior to index device-detected AF episode;
Excluding amiodarone;
Non-dihydropyridine
AAD: antiarrhythmic drug; ACE-I: angiotensin converting enzyme inhibitor; AF: atrial fibrillation; ARB: angiotensin receptor blocker; ICD: implantable cardioverter defibrillator; ICM: insertable cardiac monitor; MI: myocardial infarction; OAC: oral anticoagulation; PPM: permanent pacemaker; SD: standard deviation; TIA: transient ischemic attack